Dr. F. DuBois Bowman Named 13th President Of Morehouse
Source: Photo courtesy of the University of Michigan School of Public Health
Congratulations are in order for public health leader, Dr. F. DuBois Bowman. On Tuesday (May 13), Morehouse named the renowned biostatistician the 13th president of the Atlanta-based HBCU. Dr. Bowman will assume the role on July 15, succeeding President David A. Thomas, who began his tenure in 2018. Dr. Bowman's career story
Dr. Bowman, a distinguished authority in the statistical analysis of complex, large-scale data, became dean of the University of Michigan School of Public Health in 2018. Since taking the helm, Dr. Bowman spearheaded a bold interdisciplinary research initiative focused on addressing critical public health challenges, including firearm injury prevention, urban health equity, infectious disease control, and the advancement of health equity.
According to the University of Michigan School of Public Health website, under Dr. Bowman's guidance, the school's research funding has grown to exceed $100 million annually. He also oversaw the enhancement and expansion of academic programs at the university that currently serves more than 1,200 students.
Dr. Bowman is a member of the National Academy of Medicine and a fellow of both the American Statistical Association and the American Association for the Advancement of Science. For Bowman, a 1992 graduate of Morehouse College, this marks a full-circle moment in his journey as a public health leader. A proud member of Phi Beta Kappa and Omega Psi Phi Fraternity, Inc., he has remained deeply engaged with his alma mater—not only as a two-time Morehouse parent but also as a mentor and advocate.
He has played a key role in creating a pipeline program connecting students from Morehouse and Spelman Colleges to opportunities at the University of Michigan. In recognition of his contributions, Bowman received Morehouse's highest alumni honor in 2019, the Bennie Trailblazer Award, named after the College's sixth president, Dr. Benjamin Elijah Mays. The award recognizes alumni who have made significant contributions to their fields and have served as positive role models for others.
'Returning to Morehouse as its 13th president is the honor of a lifetime,' Dr. Bowman said in a statement. 'This institution shaped who I am—instilling a commitment to excellence, justice, and impact. I am excited to partner with faculty, staff, students, alumni, and supporters to build on our legacy and write the next chapter of Morehouse's transformative story.'
Willie Woods, the chairman of the Morehouse College Board of Trustees, called the former Columbia University and Emory University educator a 'visionary.' Woods expressed his excitement to see how Dr. Bowman will continue to shape and impact Morehouse as president.
'Dr. Bowman's record of visionary leadership, his deep commitment to academic excellence, and his lifelong dedication to Morehouse make him the ideal choice to lead the college into its next era,' Woods shared. 'He brings an extraordinary blend of intellectual rigor, strategic thinking, and values-driven leadership.'
According to 11Alive , President Thomas will step down in June. Prior to the announcement of Dr. Bowman as his successor, the 68-year-old shared with the outlet that he felt the time was right for a transition, a generational shift in leadership that will hopefully breathe new life into Morehouse.
'I think it's time for the baby boomers to leave this stage,' he added. 'The generation behind us has new ideas, new ways of engaging.'
SEE ALSO
Dr. F. DuBois Bowman Named 13th President Of Morehouse was originally published on newsone.com
Black America Web Featured Video
CLOSE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Healthcare firm Totally collapses but divisions sold
Former NHS 111 urgent care provider Totally (TLY.L) has collapsed into administration, but said a deal to sell its main divisions will see the 'uninterrupted provision' of all its services. Totally has shed about half its workforce since last year and around 100 jobs are being put at risk as part of the deal announced on Monday. The Derby-based healthcare firm – which lost the NHS 111 support contract in February this year – has appointed Ernst & Young partners Tim Vance and Sam Woodward as joint administrators after failing to secure bids or strategic investors for the entire firm. It said that following the appointment, the sale of its selective care and corporate wellbeing subsidiaries, as well as the urgent care division, was completed to rival PHL Group. 'This transaction sees the continued and uninterrupted provision of all services previously delivered by the group,' Totally said. Totally employed around 1,400 staff at the end of March 2024. By the time it appointed administrators at EY on Friday, it had some 750 employees following two rounds of redundancies. More than 600 of those have been immediately transferred to the new owners following the sale to PHL – meaning that some 100 roles are at risk of redundancy. Mr Vance said: 'We are pleased to have agreed the sale of Totally which safeguards critical frontline NHS services and includes the retention of over 600 jobs.' Totally added: 'PHL Group will make separate announcements shortly, including communication with the customers, suppliers and employees of the elective care and urgent care divisions, and the corporate wellbeing business, which are all continuing to provide all services as normal following the transaction.' The company's failure comes after a difficult past year, with the firm losing the NHS 111 contract worth £13 million and then revealing last month it was facing a potential medical negligence claim related to an incident in January 2018. At the time, it warned the size of the liability for the claim could be more than the £10 million claim limit on its insurance policy. It launched a strategic review to look at options, including the sale of subsidiaries 'receiving strategic investment or undertaking some other form of comparable corporate action'. Shares in the firm plummeted at the time. On June 6, it announced its intention to appoint administrators after the review had failed to see any 'solvent' offers for parent firm Totally and suspended its shares from trading on London's junior Aim market. PHL – the buyer of its trading divisions – was launched in 2009 and runs services in the UK and overseas, including integrated urgent care, urgent treatment centres, surgical insourcing, custody healthcare, ADHD services and general practice.
Yahoo
an hour ago
- Yahoo
Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
National Platform Offers Secure Access to Physician-Led TRT and Hormone Health Consultations from Anywhere in the U.S. VERO BEACH, June 10, 2025 (GLOBE NEWSWIRE) -- PeterMD, a Florida-based men's health telemedicine provider, has updated its official website to spotlight its nationwide services focused on testosterone replacement therapy (TRT), hormone optimization, and performance support. Available in all 50 states, PeterMD offers direct-to-consumer access to licensed providers via a secure digital platform. According to the official website ( PeterMD allows adult men to privately consult with certified TRT specialists, receive personalized treatment plans based on lab results, and manage therapy from the comfort of home. Services are available without insurance requirements, with fast turnaround times and HIPAA-compliant care. 'PeterMD was built to eliminate unnecessary barriers to men's health,' said a company spokesperson. 'We believe in transparent, physician-directed care that gives men control over their wellness without waiting rooms or stigma.' The telemedicine platform includes options for lab testing coordination, treatment supervision, and ongoing patient support. Every consultation is handled by a qualified medical professional trained in men's hormone health. Once a plan is approved, therapies are shipped directly with complete oversight from the PeterMD medical team. The updated site features secure registration, FAQs, and real-time access to specialists. New clients are invited to speak directly with a TRT specialist by calling or texting 772-800-6133. For existing patients, dedicated support is available at 772-444-8669 or via email at support@ PeterMD patient support hours: Monday–Sunday: 7 AM – 7 PM EST (for new inquiries) Monday–Friday: 9 AM – 5 PM EST (for existing patients) About PeterMD PeterMD is a telehealth provider based in Vero Beach, Florida, offering customized men's hormone and wellness solutions across the United States. The platform connects users with medical experts for private, fast, and clinically guided treatment—empowering men to reclaim their energy, focus, and vitality through modern, accessible care. Product and Contact Information Brand: PeterMDWebsite: support@ (New Patients): 772-800-6133Phone (Support): 772-444-8669Mailing Address: 601 21st Street, Suite 300, Vero Beach, FL, United StatesBusiness Hours:New Patients: Monday–Sunday, 7 AM – 7 PM ESTSupport: Monday–Friday, 9 AM – 5 PM EST Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All medical decisions should be made in consultation with a licensed healthcare provider. Availability of telemedicine services may vary by state. PeterMD complies with all applicable healthcare regulations. CONTACT: Email: support@ Phone (New Patients): 772-800-6133 Phone (Support): 772-444-8669Sign in to access your portfolio
